The Effect of mRNA-Based COVID-19 Vaccination on Anti-Programmed Cell Death Protein 1 Blockade for Nasopharyngeal Cancer May Differ From a Virus-Inactivated Vaccine

Takuma Hayashi^{1

2}, Ikuo Konishi^{1

2

3}

Affiliations

¹ Cancer Medicine, National Hospital Organization Kyoto Medical Centre, Kyoto, Japan.
² Department of Medical R&D Promotion Project, The Japan Agency for Medical Research and Development (AMED), Tokyo, Japan.
³ Department of Obstetrics and Gynecology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Takuma Hayashi et al. World J Oncol. 2023 Aug.

. 2023 Aug;14(4):316-320.

doi: 10.14740/wjon1620. Epub 2023 Jul 12.

Takuma Hayashi^{1

2}, Ikuo Konishi^{1

2

3}

¹ Cancer Medicine, National Hospital Organization Kyoto Medical Centre, Kyoto, Japan.
² Department of Medical R&D Promotion Project, The Japan Agency for Medical Research and Development (AMED), Tokyo, Japan.
³ Department of Obstetrics and Gynecology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

No abstract available

Conflict of interest statement

The authors have declared no conflict of interest.

1. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–1867. doi: 10.1056/NEJMoa1602252. - DOI - PMC - PubMed
1. Hua YJ, Liu YL, Wen K, Kurts C, Wu H, Mei Q, Li J. Potentially improved response of COVID-19 vaccinated nasopharyngeal cancer patients to combination therapy with anti-PD-1 blockade and chemotherapy. Ann Oncol. 2023;34(1):121–123. doi: 10.1016/j.annonc.2022.10.002. - DOI - PMC - PubMed
1. Ferris R, Gillison ML. Nivolumab for squamous-cell cancer of head and neck. N Engl J Med. 2017;376(6):596. doi: 10.1056/NEJMc1615565. - DOI - PubMed
1. Burtness B. et al. LBA8_PRKEYNOTE-048: phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) Ann Oncol. 2018;29(suppl_8):mdy424.045.
1. Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, Li M. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(6):803–812. doi: 10.1016/S1473-3099(20)30987-7. - DOI - PMC - PubMed